Advertising Agencies
Compare Stocks
2 / 10Stock Comparison
HHS vs MMS
Revenue, margins, valuation, and 5-year total return — side by side.
Specialty Business Services
HHS vs MMS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Advertising Agencies | Specialty Business Services |
| Market Cap | $21M | $3.64B |
| Revenue (TTM) | $160M | $5.32B |
| Net Income (TTM) | $-811K | $373M |
| Gross Margin | 41.2% | 24.6% |
| Operating Margin | 0.7% | 10.8% |
| Forward P/E | — | 7.8x |
| Total Debt | $22M | $1.44B |
| Cash & Equiv. | $6M | $260M |
HHS vs MMS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Harte Hanks, Inc. (HHS) | 100 | 121.9 | +21.9% |
| Maximus, Inc. (MMS) | 100 | 92.6 | -7.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: HHS vs MMS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
HHS is the clearest fit if your priority is income & stability and sleep-well-at-night.
- Dividend streak 0 yrs, beta 0.71
- Lower volatility, beta 0.71, current ratio 1.54x
- Beta 0.71, current ratio 1.54x
MMS carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 2.4%, EPS growth 10.4%, 3Y rev CAGR 5.5%
- 39.7% 10Y total return vs HHS's -82.7%
- 2.4% revenue growth vs HHS's -13.9%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 2.4% revenue growth vs HHS's -13.9% | |
| Quality / Margins | 7.0% margin vs HHS's -0.5% | |
| Stability / Safety | Beta 0.71 vs MMS's 0.72 | |
| Dividends | 1.8% yield; 2-year raise streak; the other pay no meaningful dividend | |
| Momentum (1Y) | +1.1% vs HHS's -42.2% | |
| Efficiency (ROA) | 8.8% ROA vs HHS's -0.9%, ROIC 15.1% vs 4.4% |
HHS vs MMS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
HHS vs MMS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
MMS leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MMS is the larger business by revenue, generating $5.3B annually — 33.3x HHS's $160M. MMS is the more profitable business, keeping 7.0% of every revenue dollar as net income compared to HHS's -0.5%. On growth, MMS holds the edge at -4.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $160M | $5.3B |
| EBITDAEarnings before interest/tax | $6M | $645M |
| Net IncomeAfter-tax profit | -$811,000 | $373M |
| Free Cash FlowCash after capex | -$4M | $372M |
| Gross MarginGross profit ÷ Revenue | +41.2% | +24.6% |
| Operating MarginEBIT ÷ Revenue | +0.7% | +10.8% |
| Net MarginNet income ÷ Revenue | -0.5% | +7.0% |
| FCF MarginFCF ÷ Revenue | -2.3% | +7.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | -15.4% | -4.1% |
| EPS Growth (YoY)Latest quarter vs prior year | +190.9% | +6.5% |
Valuation Metrics
HHS leads this category, winning 4 of 4 comparable metrics.
Valuation Metrics
On an enterprise value basis, HHS's 5.6x EV/EBITDA is more attractive than MMS's 6.7x.
| Metric | ||
|---|---|---|
| Market CapShares × price | $21M | $3.6B |
| Enterprise ValueMkt cap + debt − cash | $37M | $4.8B |
| Trailing P/EPrice ÷ TTM EPS | -25.27x | 12.10x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 7.83x |
| PEG RatioP/E ÷ EPS growth rate | — | 1.19x |
| EV / EBITDAEnterprise value multiple | 5.64x | 6.67x |
| Price / SalesMarket cap ÷ Revenue | 0.13x | 0.67x |
| Price / BookPrice ÷ Book value/share | 1.00x | 2.31x |
| Price / FCFMarket cap ÷ FCF | — | 9.93x |
Profitability & Efficiency
MMS leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
MMS delivers a 21.8% return on equity — every $100 of shareholder capital generates $22 in annual profit, vs $-4 for HHS. MMS carries lower financial leverage with a 0.86x debt-to-equity ratio, signaling a more conservative balance sheet compared to HHS's 1.09x. On the Piotroski fundamental quality scale (0–9), MMS scores 8/9 vs HHS's 2/9, reflecting strong financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -3.9% | +21.8% |
| ROA (TTM)Return on assets | -0.9% | +8.8% |
| ROICReturn on invested capital | +4.4% | +15.1% |
| ROCEReturn on capital employed | +3.4% | +17.4% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 8 |
| Debt / EquityFinancial leverage | 1.09x | 0.86x |
| Net DebtTotal debt minus cash | $17M | $1.2B |
| Cash & Equiv.Liquid assets | $6M | $260M |
| Total DebtShort + long-term debt | $22M | $1.4B |
| Interest CoverageEBIT ÷ Interest expense | 0.69x | 4.93x |
Total Returns (Dividends Reinvested)
MMS leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MMS five years ago would be worth $7,958 today (with dividends reinvested), compared to $5,388 for HHS. Over the past 12 months, MMS leads with a +1.1% total return vs HHS's -42.2%. The 3-year compound annual growth rate (CAGR) favors MMS at -4.0% vs HHS's -21.9% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -9.2% | -22.5% |
| 1-Year ReturnPast 12 months | -42.2% | +1.1% |
| 3-Year ReturnCumulative with dividends | -52.3% | -11.6% |
| 5-Year ReturnCumulative with dividends | -46.1% | -20.4% |
| 10-Year ReturnCumulative with dividends | -82.7% | +39.7% |
| CAGR (3Y)Annualised 3-year return | -21.9% | -4.0% |
Risk & Volatility
Evenly matched — HHS and MMS each lead in 1 of 2 comparable metrics.
Risk & Volatility
HHS is the less volatile stock with a 0.71 beta — it tends to amplify market swings less than MMS's 0.72 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MMS currently trades 66.7% from its 52-week high vs HHS's 51.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.71x | 0.72x |
| 52-Week HighHighest price in past year | $5.39 | $100.00 |
| 52-Week LowLowest price in past year | $2.22 | $60.75 |
| % of 52W HighCurrent price vs 52-week peak | +51.6% | +66.7% |
| RSI (14)Momentum oscillator 0–100 | 57.0 | 35.0 |
| Avg Volume (50D)Average daily shares traded | 9K | 683K |
Analyst Outlook
MMS leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
MMS is the only dividend payer here at 1.78% yield — a key consideration for income-focused portfolios.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $110.00 |
| # AnalystsCovering analysts | — | 16 |
| Dividend YieldAnnual dividend ÷ price | — | +1.8% |
| Dividend StreakConsecutive years of raises | 0 | 2 |
| Dividend / ShareAnnual DPS | — | $1.19 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.3% | +12.3% |
MMS leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). HHS leads in 1 (Valuation Metrics). 1 tied.
HHS vs MMS: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is HHS or MMS a better buy right now?
For growth investors, Maximus, Inc.
(MMS) is the stronger pick with 2. 4% revenue growth year-over-year, versus -13. 9% for Harte Hanks, Inc. (HHS). Maximus, Inc. (MMS) offers the better valuation at 12. 1x trailing P/E (7. 8x forward), making it the more compelling value choice. Analysts rate Maximus, Inc. (MMS) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — HHS or MMS?
Over the past 5 years, Maximus, Inc.
(MMS) delivered a total return of -20. 4%, compared to -46. 1% for Harte Hanks, Inc. (HHS). Over 10 years, the gap is even starker: MMS returned +39. 7% versus HHS's -82. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — HHS or MMS?
By beta (market sensitivity over 5 years), Harte Hanks, Inc.
(HHS) is the lower-risk stock at 0. 71β versus Maximus, Inc. 's 0. 72β — meaning MMS is approximately 2% more volatile than HHS relative to the S&P 500. On balance sheet safety, Maximus, Inc. (MMS) carries a lower debt/equity ratio of 86% versus 109% for Harte Hanks, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — HHS or MMS?
By revenue growth (latest reported year), Maximus, Inc.
(MMS) is pulling ahead at 2. 4% versus -13. 9% for Harte Hanks, Inc. (HHS). On earnings-per-share growth, the picture is similar: Harte Hanks, Inc. grew EPS 97. 3% year-over-year, compared to 10. 4% for Maximus, Inc.. Over a 3-year CAGR, MMS leads at 5. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — HHS or MMS?
Maximus, Inc.
(MMS) is the more profitable company, earning 5. 9% net margin versus -0. 5% for Harte Hanks, Inc. — meaning it keeps 5. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MMS leads at 10. 6% versus 1. 4% for HHS. At the gross margin level — before operating expenses — MMS leads at 23. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — HHS or MMS?
In this comparison, MMS (1.
8% yield) pays a dividend. HHS does not pay a meaningful dividend and should not be held primarily for income.
07Is HHS or MMS better for a retirement portfolio?
For long-horizon retirement investors, Maximus, Inc.
(MMS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 72), 1. 8% yield). Both have compounded well over 10 years (MMS: +39. 7%, HHS: -82. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between HHS and MMS?
These companies operate in different sectors (HHS (Communication Services) and MMS (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: HHS is a small-cap quality compounder stock; MMS is a small-cap deep-value stock. MMS pays a dividend while HHS does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.